Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 19/20 | 0.83 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20712283 | 1.00 | GLS (0.83) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21501873 | 1.00 | GLS (0.83) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL17223848 | 1.00 | GLS (0.83) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL17223842 | 1.00 | GLS (0.83) | GLSNPC1ALDH1A1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL18527463 | 0.99 | GLS (0.81) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21501861 | 0.95 | GLS (0.76) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21325734 | 0.95 | GLS (0.76) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21501842 | 0.95 | GLS (0.76) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL20712333 | 0.95 | GLS (0.76) | GLSNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21501822 | 0.95 | GLS (0.76) | GLSNPC1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676471-B2 | Cycloalkyl-linked diheterocycle derivatives | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3137460-B1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | PFIZER (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556757-A1 | CYCLOALKYL-LINKED DIHETEROCYCLE DERIVATIVES | Pfizer Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190270737-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190040055-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20180148441-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148441-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170050958-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050958-A1 | Cycloalkyl-Linked Diheterocycle Derivatives | PFIZER INC. (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.